This review highlights the current consensus management of diabetic nephropathy and identifies promising clinical biomarkers for future therapies.
No takes yet. Share an insight, caveat, or question.
Multifactorial DN care shows specialized promise; leaves open translation to routine practice and need for new biomarkers/therapies.
Montero et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: